A prospective, randomized, placebo-controlled trial of zoledronic acid in bony metastatic bladder cancer

International Journal of Clinical Oncology

Volumn 15, Issue 4, 2010, Pages 382-389

  Zaghloul, Mohamed S ^a,b   Boutrus, Rimoun ^a   El Hossieny, Hisham ^a   Kader, Yasser Abdel ^a   El Attar, Inas ^a   Nazmy, Mohamed ^a  

^a CAIRO UNIVERSITY   (Egypt)

^b CHILDREN S CANCER HOSPITAL   (Egypt)

Author keywords

Bisphosphonates; Bladder cancer; Bone metastasis; Multiple event analysis; Skeletal related events; Zoledronic acid

Indexed keywords

ANALGESIC AGENT; PLACEBO; ZOLEDRONIC ACID;

ADULT; AGED; ARTICLE; BLADDER CANCER; BONE METASTASIS; BONE NECROSIS; BONE PAIN; CANCER INCIDENCE; CANCER PAIN; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISTANT METASTASIS; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERCALCEMIA; INJECTION SITE REACTION; MALE; PATHOLOGIC FRACTURE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; SIDE EFFECT; SPINAL CORD COMPRESSION; SURVIVAL RATE; SURVIVAL TIME; TREATMENT DURATION; TREATMENT OUTCOME; UVEITIS;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; DIPHOSPHONATES; DRUG ADMINISTRATION SCHEDULE; EGYPT; FEMALE; FRACTURES, BONE; HUMANS; HYPERCALCEMIA; IMIDAZOLES; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PAIN; PLACEBO EFFECT; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SPINAL CORD COMPRESSION; TIME FACTORS; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 77955457605     PISSN: 13419625     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10147-010-0074-5     Document Type: Article

References (28)

1. Parkin DM, Bray F, Ferlay J et al (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74-108
2. Parkin DM (2008) The global burden of urinary bladder cancer. Scand J Urol Nephrol Suppl 218:12-20
3. Zaghloul MS (2006) Adjuvant radiation therapy for locally advanced bladder cancer. In: US Oncological Disease. Touch Briefings, London, pp 86-89
4. Miller LS (1977) Bladder cancer: Superiority of preoperative irradiation and cystectomy in clinical stages B2 and C. Cancer 39:973-980
5. Zaghloul MS (1996) Distant metastasis from bilharzial bladder cancer. Cancer 77:743-749
6. Volkmer BG, Kuefer R, Bartsch GC Jr et al (2009) Oncological followup after radical cystectomy for bladder cancer-is there any benefit? J Urol 181:1587-1593 (discussion 1593)
7. Rosen LS, Gordon D, Tchekmedyian NS et al (2004) Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: A randomized, phase III, double-blind, placebo- controlled trial. Cancer 100:2613-2621
8. Rosen LS, Gordon D, Tchekmedyian S et al (2003) Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: A phase III, double-blind, randomized trial-the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol 21:3150-3157
9. Rosen LS, Gordon D, Kaminski M et al (2003) Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: A randomized, double-blind, multicenter, comparative trial. Cancer 98:1735-1744
10. Saad F, Gleason DM, Murray R et al (2004) Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 96:879-882 (Pubitemid 38807610)
11. Cleeland CS, Ryan KM (1994) Pain assessment: Global use of the brief pain inventory. Ann Acad Med Singapore 23:129-138
12. Cook RJ, Lawless JF (2002) Analysis of repeated events. Stat Methods Med Res 11:141-166
13. Lipton A (2007) Treatment of bone metastases and bone pain with bisphosphonates. Support Cancer Ther 4:92-100
14. Saad F (2008) New research findings on zoledronic acid: Survival, pain, and anti-tumour effects. Cancer Treat Rev 34:183-192
15. Saad F, Lipton A (2007) Clinical benefits and considerations of bisphosphonate treatment in metastatic bone disease. Semin Oncol 34:S17-S23
16. Coleman RE (2001) Metastatic bone disease: Clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 27:165-176
17. Weinfurt KP, Anstrom KJ, Castel LD et al (2006) Effect of zoledronic acid on pain associated with bone metastasis in patients with prostate cancer. Ann Oncol 17:986-989
18. Mystakidou K, Katsouda E, Parpa E et al (2005) Randomized, open label, prospective study on the effect of zoledronic acid on the prevention of bone metastases in patients with recurrent solid tumors that did not present with bone metastases at baseline. Med Oncol 22:195-201
19. Aviles A, Nambo MJ, Neri N et al (2007) Antitumor effect of zoledronic acid in previously untreated patients with multiple myeloma. Med Oncol 24:227-230
20. Zarogoulidis K, Boutsikou E, Zarogoulidis P et al (2009) The impact of zoledronic acid therapy in survival of lung cancer patients with bone metastasis. Int J Cancer 125:1705-1709
21. Guise TA (2008) Antitumor effects of bisphosphonates: Promising preclinical evidence. Cancer Treat Rev 34[Suppl 1]:S19-S24
22. Winter MC, Holen I, Coleman RE (2008) Exploring the antitumour activity of bisphosphonates in early breast cancer. Cancer Treat Rev 34:453-475
23. Wood J, Bonjean K, Ruetz S et al (2002) Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther 302:1055-1061
24. Tas F, Duranyildiz D, Oguz H et al (2008) Effect of zoledronic acid on serum angiogenic factors in patients with bone metastases. Med Oncol 25:346-349
25. Kunzmann V, Bauer E, Feurle J et al (2000) Stimulation of gammadelta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. Blood 96:384-392
26. Santini D, Martini F, Fratto ME et al (2009) In vivo effects of zoledronic acid on peripheral gammadelta T lymphocytes in early breast cancer patients. Cancer Immunol Immunother 58:31-38
27. Gnant M, Mlineritsch B, Schippinger W et al (2009) Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 360:679-691
28. Brufsky A, Bundred N, Coleman R et al (2008) Integrated analysis of zoledronic acid for prevention of aromatase inhibitorassociated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole. Oncologist 13:503-514 (Pubitemid 351872868)